

Company compiled consensus - average, high, low estimates

Last updated 30 September 2026

*** Please note: These numbers predate the ad hoc trading update and guidance upgrades on 7 October 2026 ***

Consensus	2026 (excl. KARE)			2027 (incl. KARE)			2028 (incl. KARE)		
£'m (unless stated otherwise)	Average	High	Low	Average	High	Low	Average	High	Low
AUM									
Total AUM (€ billion)	89	97	84	110	119	95	120	136	102
FPAUM (€ billion)	50	55	45	70	83	53	81	96	58
P&L									
Management fees and other income	520	536	481	732	757	548	798	846	606
Expenses before exceptional expenses	(299)	(292)	(307)	(380)	(312)	(387)	(406)	(331)	(420)
Underlying FRE	221	236	182	351	370	227	392	459	267
<i>Underlying FRE margin</i>	<i>42%</i>	<i>44%</i>	<i>38%</i>	<i>48%</i>	<i>50%</i>	<i>41%</i>	<i>49%</i>	<i>54%</i>	<i>44%</i>
PRE	178	191	158	194	212	158	253	265	201
Underlying EBITDA	400	424	340	545	567	416	645	724	468
<i>Underlying EBITDA margin</i>	<i>57%</i>	<i>59%</i>	<i>53%</i>	<i>59%</i>	<i>62%</i>	<i>56%</i>	<i>61%</i>	<i>65%</i>	<i>58%</i>
Underlying PBT	339	370	285	462	484	363	571	657	412
Income tax	(51)	(39)	(61)	(79)	(54)	(82)	(98)	(62)	(114)
Underlying PAT	288	316	242	383	402	308	473	543	351
No. of shares	1,038	1,044	1,034	1,238	1,331	1,036	1,244	1,331	1,061
Underlying EPS (pence)	27.8	30.4	23.2	31.0	34.9	29.1	38.3	48.6	32.4

Notes

1. Columns represent the average, highest and lowest analyst estimates for each line item and are not additive. Therefore, total values may not tie to the sum of components

Disclaimer



Last updated 30 September 2026

*** Please note: These numbers predate the ad hoc trading update and guidance upgrades on 7 October 2026 ***

The following analysts have published a forecast for Bridgepoint since the announcement of the KARE transaction on 29 June 2026 and have been included in this Company compiled consensus:

Analyst coverage included in consensus, by year

Analyst	2026	2027	2028
Berenberg	✓	✓	✓
BNP Paribas*	✓	✓	✓
Cavendish	✓	✓	✓
Citi	✓	✓	✓
Deutsche Numis	✓	✓	✓
Investec	✓	–	–
Jefferies	✓	✓	✓
Morgan Stanley*	✓	–	–

*Corporate Brokers to Bridgepoint Group plc

This document contains a collation of forecasts which have been provided to Bridgepoint Group plc (“Bridgepoint”) by registered investment analysts. Bridgepoint does not express any opinion on, or endorse in any way, the consensus information and the underlying forecasts do not represent the opinions, forecasts, estimates or projects of the Bridgepoint or its management.

It should be noted that forecasts are by definition forward looking and are therefore subject to risks and uncertainties that may materially affect eventual results. Bridgepoint, its affiliates and their respective directors, officers and employees accept no responsibility for the accuracy of the forecasts used in this document and therefore shall have no liability whatsoever for the consequences of any reliance or actions taken or not taken based on any of the information in this document.

Nothing in this document should be taken as a recommendation to buy or sell shares in Bridgepoint or any other securities or investments, nor a recommendation to take any other action or place any reliance on this document.

Bridgepoint assumes no obligation to update or revise the information in this document to reflect circumstances existing after the date hereof.

For all queries regarding consensus, please contact shareholders@bridgepoint.eu.